A new study published in Microbial Biotechnology sheds light on the microbes living inside the mucin of pseudomyxoma peritonei (PMP). For years, researchers have suspected that bacteria may play a role in PMP. This study goes further – and identifies fungi in PMP mucin for the first time. What the researchers found Living bacteria were recovered from most of the...

Could existing medications help expand surgical options for patients with appendix cancer? A newly launched clinical trial at the Allegheny Health Network (AHN) Cancer Center in Pittsburgh is exploring an innovative approach to a challenge faced by some patients with appendix cancer and other peritoneal malignancies: dense scar tissue (fibrosis) that can make surgery more difficult or, in some cases,...

Meet The Appy Files, ACPMP's new podcast bringing together expert insights and community connection to explore the latest in appendix cancer research. The podcast is hosted by ACPMP Patient Liaison Shannon Altpeter, DMSc, PA-C, a surgical oncology physician assistant at Allegheny Health Network. Episode 1: TLR9 immunotherapy for peritoneal carcinomatosis In our first episode, Shannon sits down with Dr. Khaldoun...

Missed the 2026 Appendix Cancer Multi-Regional Symposium, or want to rewatch a session? Recordings of ACPMP's annual virtual symposium, held on Friday, October 2, 2026, are now available to watch for free. The symposium is ACPMP's largest educational event of the year. More than 500 patients, survivors, caregivers, and healthcare professionals registered to hear internationally recognized experts discuss the latest...

The grant funds research by Dr. Mohammad Haroon Choudry of UPMC Hillman Cancer Center on crossing the mucinous barrier that keeps therapies from reaching tumors Research is how we change the future of appendix cancer. Dr. Choudry's work goes directly at one of the hardest problems in treating PMP, and we are proud to support it in Katie's memory”— Jim...

A new investigational treatment is being studied for appendiceal and colorectal cancers that have spread within the abdomen. A Phase 1 clinical trial at Brown University Health is testing ACM-CpG, an experimental immunotherapy being developed by Arcamyra Therapeutics. How ACM-CpG works ACM-CpG is designed to be delivered directly into the abdominal cavity, where it may help stimulate the immune system...

On August 26, 2026, the U.S. Food and Drug Administration (FDA) approved daraxonrasib (brand name Rasonque), a new targeted therapy that blocks multiple forms of the RAS protein, for adults with metastatic pancreatic cancer. About the approval Daraxonrasib is a once-daily pill developed by Revolution Medicines. It is approved for adults with metastatic pancreatic adenocarcinoma who have already received at...

Governor Evers proclaims the month as landmarks light amber for ACPMP's awareness initiative, alongside a new MCW course and the Living4Lindsey Foundation. Wisconsin shows what awareness looks like when a community comes together: a proclamation, landmarks lit amber, physicians learning more about the disease, and families like the Jacobs leading the way”— Jim Carroll, ACPMP Board President WI, UNITED STATES,...

Governor Shapiro issued a statement of recognition as landmarks globally light amber for the Pennsylvania-based nonprofit ACPMP's annual awareness initiative. To have our home state recognize the month, while a dozen states proclaim it and landmarks around the world light amber, tells patients and families facing appendix cancer that they are not alone”— Judy Culbertson, Board Vice President of ACPMP...

Researchers are testing zoldonrasib, a new targeted drug designed to block the KRAS G12D mutation – a genetic change that helps drive the growth of many pancreatic cancers. Early results, presented at the 2026 ESMO Gastrointestinal Cancers Congress, are encouraging. What the study found In an early-stage study of 81 people with previously untreated metastatic pancreatic cancer carrying the KRAS...